261 related articles for article (PubMed ID: 24105684)
1. Biomarkers of drugs targeting HER-family signalling in cancer.
Montemurro F; Scaltriti M
J Pathol; 2014 Jan; 232(2):219-29. PubMed ID: 24105684
[TBL] [Abstract][Full Text] [Related]
2. Targeting HER family in HER2-positive metastatic breast cancer: potential biomarkers and novel targeted therapies.
Monteiro Ide P; Madureira P; de Vasconscelos A; Pozza DH; de Mello RA
Pharmacogenomics; 2015; 16(3):257-71. PubMed ID: 25712189
[TBL] [Abstract][Full Text] [Related]
3. The Evolving Landscape of HER2 Targeting in Breast Cancer.
Moasser MM; Krop IE
JAMA Oncol; 2015 Nov; 1(8):1154-61. PubMed ID: 26204261
[TBL] [Abstract][Full Text] [Related]
4. Update on HER-kinase-directed therapy in prostate cancer.
Gross ME; Jo S; Agus DB
Clin Adv Hematol Oncol; 2004 Jan; 2(1):53-6, 64. PubMed ID: 16163160
[TBL] [Abstract][Full Text] [Related]
5. HER2 testing in gastric cancer: An update.
Abrahao-Machado LF; Scapulatempo-Neto C
World J Gastroenterol; 2016 May; 22(19):4619-25. PubMed ID: 27217694
[TBL] [Abstract][Full Text] [Related]
6. HER3/ErbB3, an emerging cancer therapeutic target.
Zhang N; Chang Y; Rios A; An Z
Acta Biochim Biophys Sin (Shanghai); 2016 Jan; 48(1):39-48. PubMed ID: 26496898
[TBL] [Abstract][Full Text] [Related]
7. The interplay of HER2/HER3/PI3K and EGFR/HER2/PLC-γ1 signalling in breast cancer cell migration and dissemination.
Balz LM; Bartkowiak K; Andreas A; Pantel K; Niggemann B; Zänker KS; Brandt BH; Dittmar T
J Pathol; 2012 Jun; 227(2):234-44. PubMed ID: 22262199
[TBL] [Abstract][Full Text] [Related]
8. Targeting HER proteins in cancer therapy and the role of the non-target HER3.
Hsieh AC; Moasser MM
Br J Cancer; 2007 Aug; 97(4):453-7. PubMed ID: 17667926
[TBL] [Abstract][Full Text] [Related]
9. The upgraded role of HER3 and HER4 receptors in breast cancer.
Koutras AK; Fountzilas G; Kalogeras KT; Starakis I; Iconomou G; Kalofonos HP
Crit Rev Oncol Hematol; 2010 May; 74(2):73-8. PubMed ID: 19481955
[TBL] [Abstract][Full Text] [Related]
10. CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity.
Lai CJ; Bao R; Tao X; Wang J; Atoyan R; Qu H; Wang DG; Yin L; Samson M; Forrester J; Zifcak B; Xu GX; DellaRocca S; Zhai HX; Cai X; Munger WE; Keegan M; Pepicelli CV; Qian C
Cancer Res; 2010 May; 70(9):3647-56. PubMed ID: 20388807
[TBL] [Abstract][Full Text] [Related]
11. An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa) -induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review).
Ferrer-Soler L; Vazquez-Martin A; Brunet J; Menendez JA; De Llorens R; Colomer R
Int J Mol Med; 2007 Jul; 20(1):3-10. PubMed ID: 17549382
[TBL] [Abstract][Full Text] [Related]
12. HER2-family signalling mechanisms, clinical implications and targeting in breast cancer.
Elster N; Collins DM; Toomey S; Crown J; Eustace AJ; Hennessy BT
Breast Cancer Res Treat; 2015 Jan; 149(1):5-15. PubMed ID: 25542271
[TBL] [Abstract][Full Text] [Related]
13. Biomarkers for Predicting Response to Anti-HER2 Agents.
Varadan V; Sandoval M; Harris LN
Adv Exp Med Biol; 2016; 882():155-67. PubMed ID: 26987534
[TBL] [Abstract][Full Text] [Related]
14. Novel agents that downregulate EGFR, HER2, and HER3 in parallel.
Ferreira RB; Law ME; Jahn SC; Davis BJ; Heldermon CD; Reinhard M; Castellano RK; Law BK
Oncotarget; 2015 Apr; 6(12):10445-59. PubMed ID: 25865227
[TBL] [Abstract][Full Text] [Related]
15. HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells.
Hirata A; Hosoi F; Miyagawa M; Ueda S; Naito S; Fujii T; Kuwano M; Ono M
Cancer Res; 2005 May; 65(10):4253-60. PubMed ID: 15899817
[TBL] [Abstract][Full Text] [Related]
16. Neratinib, A Novel HER2-Targeted Tyrosine Kinase Inhibitor.
Tiwari SR; Mishra P; Abraham J
Clin Breast Cancer; 2016 Oct; 16(5):344-348. PubMed ID: 27405796
[TBL] [Abstract][Full Text] [Related]
17. Targeting HER1/EGFR: a molecular approach to cancer therapy.
Arteaga C
Semin Oncol; 2003 Jun; 30(3 Suppl 7):3-14. PubMed ID: 12840796
[TBL] [Abstract][Full Text] [Related]
18. Management of Metastatic HER2-Positive Breast Cancer: Where Are We and Where Do We Go From Here?
Santa-Maria CA; Nye L; Mutonga MB; Jain S; Gradishar WJ
Oncology (Williston Park); 2016 Feb; 30(2):148-55. PubMed ID: 26892151
[TBL] [Abstract][Full Text] [Related]
19. Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: a randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie.
Lorenzen S; Riera Knorrenschild J; Haag GM; Pohl M; Thuss-Patience P; Bassermann F; Helbig U; Weißinger F; Schnoy E; Becker K; Stocker G; Rüschoff J; Eisenmenger A; Karapanagiotou-Schenkel I; Lordick F
Eur J Cancer; 2015 Mar; 51(5):569-76. PubMed ID: 25694417
[TBL] [Abstract][Full Text] [Related]
20. Effective treatment of HER2-amplified breast cancer by targeting HER3 and β1 integrin.
Campbell MR; Zhang H; Ziaee S; Ruiz-Saenz A; Gulizia N; Oeffinger J; Amin DN; Ahuja D; Moasser MM; Park CC
Breast Cancer Res Treat; 2016 Feb; 155(3):431-40. PubMed ID: 26860947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]